Twain Therapeutics is developing multi-specific biologics that utilize antibody-based IL-2 receptor agonists to enhance cytotoxic T cell-mediated anti-tumor responses with minimal side effects. This approach provides a safer and more effective therapeutic option for cancer patients facing the limitations of current treatment methods.
Funding
$6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatments often struggle to effectively stimulate the immune system's cytotoxic T cells to target and eliminate tumors, while also minimizing harmful side effects. Existing immunotherapies can cause systemic toxicity, limiting their efficacy and tolerability in a broad range of patients.
Solution
Twain Therapeutics is developing multi-specific biologics that selectively activate the IL-2 receptor on cytotoxic T cells within the tumor microenvironment, enhancing their anti-tumor activity. By utilizing antibody-based IL-2 receptor agonists, Twain's approach aims to improve the precision and potency of immune responses against cancer cells. This targeted activation minimizes off-target effects, reducing the risk of systemic immune-related adverse events. The biologics are designed for subcutaneous administration and extended half-life, offering a more convenient and potentially more effective treatment option.
Target Audience
Twain Therapeutics' primary target audience includes cancer patients who may benefit from more effective and less toxic immunotherapies, as well as oncologists and researchers seeking novel approaches to cancer treatment.
Features
- Multi-specific antibody-based IL-2 receptor agonists
- Selective activation of cytotoxic T cells within the tumor microenvironment
- Enhanced cytotoxic T cell-mediated anti-tumor responses
- Minimized systemic toxicity and off-target effects
- Extended half-life for less frequent dosing
- Subcutaneous administration for patient convenience